There is no shortage of investors who are bullish on VBI Vaccines Inc. (VBIV) stock

VBI Vaccines Inc. [VBIV] stock prices are up down -3.87% to $0.73 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VBIV shares have lost -10.96% over the last week, with a monthly amount drifted -27.46%, and not seem to be holding up well over a long-time horizon.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 21, September 2022, VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting. In a post published today on Yahoo Finance, VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated compassionate use of VBI’s 3-antigen hepatitis B vaccine in four adults chronically infected with hepatitis B virus (HBV) were presented in a poster session at the 2022 International HBV Meeting in Paris, France, on September 19.

From an analyst’s perspective:

Previously, Jefferies started tracking the stock with Buy rating on February 25, 2021, and set its price target to $7. On August 27, 2020, upgrade upgraded it’s rating to Strong Buy and revised its price target to $9 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $9 on January 16, 2019. Canaccord Genuity initiated its recommendation with a Buy and recommended $10 as its price target on November 01, 2017. Laidlaw started tracking with a Buy rating for this stock on October 10, 2016, and assigned it a price target of $6. In a note dated July 26, 2016, Ladenburg Thalmann initiated an Buy rating.

The stock price of VBI Vaccines Inc. [VBIV] has been fluctuating between $0.64 and $3.49 over the past year. Currently, Wall Street analysts expect the stock to reach $6.00 within the next 12 months. VBI Vaccines Inc. [NASDAQ: VBIV] shares were valued at $0.73 at the most recent close of the market. An investor can expect a potential return of 721.92% based on the average price forecast.

Analyzing the VBIV fundamentals

The most recent quarter, VBI Vaccines Inc. [NASDAQ:VBIV] reported sales of 346.0 million, representing a surge of 200.00%. Gross Margin for this corporation currently stands at -1897.62% with Operating Margin at -10781.62%, Pretax Margin comes in at -11054.36%, and Net Margin reading is -11054.36%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7051 points at the first support level, and at 0.6776 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7701, and for the 2nd resistance point, it is at 0.8076.

VBI Vaccines Inc. [VBIV] reported earnings per share of -$0.08 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.08/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.07 per share as compared to estimates of -$0.07 per share, a difference of $0 representing a surprise of 0.00%.

Ratios To Look Out For

It’s worth pointing out that VBI Vaccines Inc. [NASDAQ:VBIV]’s Current Ratio is 2.30. In addition, the Quick Ratio stands at 3.92 and the Cash Ratio stands at 3.73. Considering the valuation of this stock, the price to sales ratio is 945.45, the price to book ratio is 4.20.

Transactions by insiders

In the past 3 months, 0 insiders have purchased 0 shares, and 0 have sold 0 shares. Recent insider trading involved Beattie Nell, Chief Business Officer, that happened on Dec 03 when 8200.0 shares were purchased. 10% Owner, PERCEPTIVE ADVISORS LLC completed a deal on Dec 01 to sell 2.71 million shares.